Short answer
AMICUS THERAPEUTICS, INC. (FOLD) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $169M (up 19.5% year over year) with net income of $17M.
Q3 2025 key financials · XBRL
- Revenue
- $169M
- +19.5% YoY · +9.3% QoQ
- Net income
- $17M
- +357.2% YoY · +170.9% QoQ
- Operating margin
- 20.3%
- Gross margin
- 88.5%
- EPS (diluted)
- $0.06
- +400.0% YoY · +175.0% QoQ
Source: XBRL data from the AMICUS THERAPEUTICS, INC. (FOLD) Q3 2025 10-Q on SEC EDGAR. USD.
AMICUS THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or changed risk factors disclosed since 2024 10-K
- Carried-forward regulatory risk: reliance on FDA approvals for product pipeline advancement
- Operational risk: dependence on third-party manufacturing affecting supply chain continuity
- Market risk: competition from alternative therapies potentially impacting market share
- Financial risk: limited liquidity with cash runway through mid-2025 requiring additional funding
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.